Registration Deadline:
Explore other Industry Opportunities:
A1: Oncology
Immunooncology
- Technologies for inducing and evaluating intratumoral TLS/HEV
- Novel neoantigens enabling off-the-shelf approaches
- Technologies to identify neoantigens derived from human cancer cells and detect immune responses induced by therapeutic agents
- NK cell engager
- In vivo/in vitro models exhibiting resistance to immune checkpoint inhibitors
- Human immune system-mimicking mouse models for simultaneous evaluation of drug efficacy and safety
- Liquid biopsy-related technologies or markers applicable as PD markers for tumor immune activation
Tumor-specific binders/technologies
- Tumor-specific antibody-related molecules for cancer therapy
- Targeting two molecules in close proximity on the cell membrane
- Functional molecules and activatable prodrug technologies responsive to tumor environment
- Technology for identifying small-molecule binders to tumor-specific proteins
- Research on target molecules or technologies for improving tumor microenvironment
- Tumor-targeted delivery technologies for oligonucleotides and proteins
Basic research on cancer
- Technologies and modalities for prevention and treatment of brain metastases
- Research on the mechanisms underlying brain metastasis and the development of relevant evaluation models
- Drug discovery for cancer theranostics
- Compounds inducing non-apoptotic programmed cell death
- Preclinical models mimicking clinical pancreatic cancer
- Protease activity analysis using FFPE samples from human tumor tissues
- Single cell proteomics and RNA-seq using CTCs
A2: CNS, Ophthalmic disease
Psychiatric disease, Neurodegenerative disease
- Exploration of neuron type-specific targets involved in the pathogenesis of schizophrenia
- Novel pathogenesis hypotheses leading to innovative drug development for schizophrenia
- Novel drug targets for neurodegenerative diseases
- Pharmacological evaluation models and biomarkers for gene therapy
- Research aimed at establishing novel drug delivery technologies for CNS drugs
Ophthalmic disease
- Drug discovery research for gene-independent therapy of retinitis pigmentosa
- Research on therapeutic targets for dry age-related macular degeneration
- Disease models of macular degeneration
- Technologies to enhance retinal infectivity of AAV administered via intravitreal injection
- Eye drop-based ocular drug delivery technologies for retinal diseases
A3: Autoimmune disease, Cardiovascular disease, Others
Autoimmune disease
- Autoimmune disease model using humanized mice that reproduce the composition of human Treg cells
- Novel lung fibrosis models mimicking human pathophysiology
Cardiovascular disease
- Identification of novel therapeutic targets based on stratification of HFpEF patients, and preclinical disease models for HFpEF
- Methods for quantitatively evaluating the peripheral ischemic pathology
- Observational study of cardiovascular diseases using wearable devices and other digital technologies
Others
- Diseases that can be treated by protease inhibition
Please note: Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.